Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Leukaemia inhibitory factor and bone cell function.

T J Martin1, E H Allan, R S Evely

  • 1Department of Medicine, University of Melbourne, Australia.

Ciba Foundation Symposium
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

Expert opinion on drug safety·2022
Same author

Bone-friendly lifestyle and the role of calcium or vitamin D supplementation.

Climacteric : the journal of the International Menopause Society·2021
Same author

Publisher Correction to: Development of the Asia Pacific Consortium on Osteoporosis (APCO) framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Management of Paget's disease of bone.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Journal of internal medicine·2019

Leukaemia inhibitory factor (LIF) is a cytokine that promotes bone resorption by acting on osteoblasts. This discovery reveals new insights into LIF

Area of Science:

  • Endocrinology
  • Cytokine Biology
  • Bone Biology

Background:

  • Leukaemia inhibitory factor (LIF) is a cytokine with known differentiation-inducing activity.
  • Its potential role in bone metabolism was previously unexplored.

Purpose of the Study:

  • To investigate the role of LIF in bone resorption and osteoblast activity.
  • To elucidate the mechanisms by which LIF influences bone cells.

Main Methods:

  • Organ culture of newborn mouse bone.
  • Studies on isolated rat osteoclasts.
  • Recombinant LIF treatment.
  • Measurement of [3H]thymidine incorporation.
  • Analysis of plasminogen activator inhibitor 1 (PAI-1) mRNA and protein synthesis.

Related Experiment Videos

Main Results:

  • Recombinant LIF promoted bone resorption in mouse bone organ culture via a prostaglandin-dependent pathway.
  • LIF enhanced resorption by isolated rat osteoclasts through a receptor-mediated action on osteoblasts.
  • LIF increased DNA synthesis in bone cells and stimulated PAI-1 synthesis in osteoblasts.
  • In vivo studies showed increased trabecular bone mass in mice with high circulating LIF levels.

Conclusions:

  • LIF is a potent cytokine affecting bone, acting on osteoblasts to modulate resorption.
  • LIF influences bone mass and may interact with other bone-active factors.
  • These findings expand the known functions of LIF beyond its established roles.